- The disease
- Soft tissue sarcoma (STS) is a group of cancers arising from connective tissues such as muscle, fat, and fibrous tissue. It accounts for a small proportion of all adult cancers but has limited treatment options, particularly in the metastatic setting. The U.S. Food and Drug Administration (FDA) has granted Veyonda (idronoxil) Orphan Drug Designation for this indication, reflecting the rarity and unmet need of the disease.
- What the asset is trying to do
- Idronoxil (Veyonda) is a small molecule described by Noxopharm as acting on two biological targets: sphingosine kinase, an enzyme involved in cell survival signalling, and the STING (stimulator of interferon genes) pathway, which plays a role in activating immune responses against cancer cells. The company states that the drug is designed to enhance the effects of chemotherapy, radiotherapy, and immunotherapy when used in combination. This dual approach differs from single-target kinase inhibitors approved in sarcoma.
- What the trial is measuring, and why it matters
- The terminated Phase 1 trial (NCT05100628) was designed to evaluate the safety and tolerability of NOX66 (a suppository formulation of idronoxil) combined with doxorubicin in anthracycline-naive adult patients with metastatic soft tissue sarcoma (per ClinicalTrials.gov NCT05100628). Doxorubicin is a standard first-line chemotherapy in this setting, making it a relevant combination partner for assessing whether idronoxil can be safely added to existing treatment. Safety and tolerability endpoints are typical for a Phase 1 dose-escalation study, as the primary goal is to identify dosing levels that do not cause unacceptable side effects before moving to larger efficacy studies.
- Efficacy benchmarks in this setting
- In the metastatic STS setting, first-line doxorubicin monotherapy has historically produced objective response rates in the range reported in published randomised trials; for example, the EORTC 62012 trial reported a response rate of 14% for single-agent doxorubicin (Seddon et al, Lancet Oncology 2017). The combination of doxorubicin plus ifosfamide produced a response rate of 26% in the same trial (Seddon et al, Lancet Oncology 2017). Olaratumab plus doxorubicin was approved based on a Phase 2 signal but later failed to confirm benefit in a Phase 3 trial (ANNOUNCE; Tap et al, JAMA 2020). Any efficacy figures from the now-terminated NOX66 plus doxorubicin Phase 1 study (NCT05100628) are not statistically comparable to these randomised trial results given the small sample size and different study design.